

|                  |   |   |
|------------------|---|---|
| <b>STN<br/>P</b> | <b>Diagnostické skúšobné systémy <i>in vitro</i><br/>Požiadavky a odporúčania na detekciu závažného<br/>akútneho respiračného syndrómu koronavírusu 2<br/>(SARS-CoV-2) metódami amplifikácie nukleovej<br/>kyseliny (ISO/TS 5798: 2022)</b> | <b>STN P<br/>CEN ISO/TS 5798</b><br><br>85 1035 |
|------------------|---|---|

In vitro diagnostic test systems - Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods (ISO/TS 5798:2022)

Táto norma obsahuje anglickú verziu európskej normy.  
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 01/23

Táto predbežná slovenská technická norma je určená na overenie. Prípadné pripomienky pošlite do novembra 2024 Úradu pre normalizáciu, metrológiu a skúšobníctvo Slovenskej republiky.

Obsahuje: CEN ISO/TS 5798:2022, ISO/TS 5798:2022

**136375**

TECHNICAL SPECIFICATION  
SPÉCIFICATION TECHNIQUE  
TECHNISCHE SPEZIFIKATION

**CEN ISO/TS 5798**

November 2022

ICS 11.100.01

English Version

**In vitro diagnostic test systems - Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods (ISO/TS 5798:2022)**

Systèmes d'essai pour diagnostic in vitro - Exigences et recommandations pour la détection du coronavirus 2 associé au syndrome respiratoire aigu sévère (SARS-CoV-2) par des méthodes d'amplification des acides nucléiques (ISO/TS 5798:2022)

In-vitro-Diagnostika-Systeme - Anforderungen und Empfehlungen für Qualitätsverfahren für den Nachweis des Coronavirus 2 des Schweren Akuten Respiratorischen Syndroms (SARS-CoV-2) mittels Nukleinsäureamplifikation (ISO/TS 5798:2022)

This Technical Specification (CEN/TS) was approved by CEN on 21 November 2022 for provisional application.

The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.

CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION  
COMITÉ EUROPÉEN DE NORMALISATION  
EUROPÄISCHES KOMITEE FÜR NORMUNG

**CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels**

**CEN ISO/TS 5798:2022 (E)**

| <b>Contents</b>               | <b>Page</b> |
|-------------------------------|-------------|
| <b>European foreword.....</b> | <b>3</b>    |

## **European foreword**

The text of ISO/TS 5798:2022 has been prepared by Technical Committee ISO/TC 212 "Clinical laboratory testing and in vitro diagnostic test systems" of the International Organization for Standardization (ISO) and has been taken over as CEN ISO/TS 5798:2022 by Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

Any feedback and questions on this document should be directed to the users' national standards body. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

## **Endorsement notice**

The text of ISO/TS 5798:2022 has been approved by CEN as CEN ISO/TS 5798:2022 without any modification.

# TECHNICAL SPECIFICATION

# ISO/TS 5798

First edition  
2022-04

---

---

## **In vitro diagnostic test systems — Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods**

*Systèmes d'essai pour diagnostic in vitro — Exigences et recommandations pour la détection du coronavirus 2 associé au syndrome respiratoire aigu sévère (SARS-CoV-2) par des méthodes d'amplification des acides nucléiques*



Reference number  
ISO/TS 5798:2022(E)

© ISO 2022

**ISO/TS 5798:2022(E)****COPYRIGHT PROTECTED DOCUMENT**

© ISO 2022

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
CP 401 • Ch. de Blandonnet 8  
CH-1214 Vernier, Geneva  
Phone: +41 22 749 01 11  
Email: [copyright@iso.org](mailto:copyright@iso.org)  
Website: [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

|  | Page      |
|--|-----------|
| <b>Foreword</b> .....  | <b>v</b>  |
| <b>Introduction</b> .....  | <b>vi</b> |
| <b>1 Scope</b> .....   | <b>1</b>  |
| <b>2 Normative references</b> .....  | <b>1</b>  |
| <b>3 Terms and definitions</b> .....   | <b>1</b>  |
| <b>4 Overview</b> .....  | <b>7</b>  |
| 4.1 SARS-CoV-2.....  | 7         |
| 4.1.1 General.....   | 7         |
| 4.1.2 Pre-examination.....   | 9         |
| 4.1.3 Examination — Overview.....  | 9         |
| 4.1.4 Post-examination.....  | 11        |
| 4.2 Nucleic acid amplification methods.....  | 11        |
| 4.2.1 Reverse transcription qPCR (RT-qPCR).....  | 11        |
| 4.2.2 Reverse transcription digital PCR (RT-dPCR).....   | 12        |
| 4.2.3 Isothermal amplification methods.....  | 12        |
| <b>5 Laboratory requirements</b> .....   | <b>12</b> |
| 5.1 General.....   | 12        |
| 5.2 Biosafety requirements.....  | 13        |
| 5.2.1 Laboratory area.....   | 13        |
| 5.2.2 Risk control.....  | 13        |
| 5.2.3 Personal protective equipment (PPE).....   | 13        |
| 5.3 General laboratory set-up.....   | 13        |
| 5.4 Instrumentation.....   | 14        |
| 5.5 Laboratory personnel.....  | 14        |
| <b>6 Design and development</b> .....  | <b>14</b> |
| 6.1 Customer, patient and stakeholder needs.....   | 14        |
| 6.2 Intended use of analytical test.....   | 14        |
| 6.3 Institutional guideline strategy.....  | 15        |
| 6.3.1 Laboratory developed tests (LDTs) versus in vitro diagnostic medical devices (IVD medical devices).....                | 15        |
| 6.3.2 Emergency use authorization.....   | 15        |
| 6.4 Clinical strategy.....   | 15        |
| 6.5 Design and development planning.....   | 16        |
| 6.5.1 Pre-examination of respiratory specimens for SARS-CoV-2 testing.....   | 16        |
| 6.5.2 Examination design specifications (analytical test specifications).....  | 22        |
| 6.5.3 Design risk management.....  | 27        |
| 6.6 Optimization of reagents and methods.....  | 28        |
| 6.6.1 Selection of SARS-CoV-2 target sequences.....  | 28        |
| 6.6.2 Potential impact of variants of concern (VOCs) on the quality of NAAT diagnostic methods for detecting SARS-CoV-2..... | 28        |
| 6.6.3 Selection of amplification methods.....  | 28        |
| 6.6.4 Design and selection of primers.....   | 28        |
| 6.6.5 Optimization of the reaction system.....   | 29        |
| 6.6.6 Determination of cut-off values.....   | 29        |
| 6.6.7 Verification and validation of test design.....  | 29        |
| <b>7 Verification for patient care</b> .....   | <b>31</b> |
| 7.1 General.....   | 31        |
| 7.2 Confirmation of analytical performance characteristics.....  | 31        |
| 7.2.1 Accuracy.....  | 31        |
| 7.2.2 Limit of detection (LOD).....  | 31        |
| 7.2.3 Inclusivity.....   | 32        |
| 7.2.4 Specificity.....   | 32        |

**ISO/TS 5798:2022(E)**

|   |   |           |
|---|---|-----------|
| 7.2.5   | Robustness.....   | 32        |
| 7.3   | Clinical evidence .....   | 33        |
| <b>8</b>  | <b>Validation for patient care.....</b>                                       | <b>33</b> |
| 8.1   | General consideration.....  | 33        |
| 8.2   | Clarification of the intended use .....                                       | 33        |
| 8.3   | Performance with clinical specimens or samples.....                           | 34        |
| <b>9</b>  | <b>Design transfer to production.....</b>                                     | <b>34</b> |
| <b>10</b>   | <b>Implementation and use in the laboratory and reporting of results.....</b> | <b>34</b> |
| 10.1  | Implementation and use in the laboratory.....                                 | 34        |
| 10.2  | Reporting and interpretation of results.....                                  | 35        |
| <b>11</b>   | <b>Quality assurance.....</b>   | <b>36</b> |
| 11.1  | Performance monitoring.....   | 36        |
| 11.2  | Design change including optimization of analytical test.....                  | 36        |
| 11.3  | Interlaboratory comparison.....   | 37        |
| <b>Annex A (informative) Nucleic acid amplification techniques.....</b> |   | <b>38</b> |
| <b>Bibliography.....</b>  |   | <b>41</b> |



## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*, in collaboration with Technical Committee ISO/TC 276, *Biotechnology*.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

## ISO/TS 5798:2022(E)

### Introduction

Coronaviruses are enveloped RNA viruses that are broadly distributed in the animal kingdom. They have been identified in humans, other mammals, and birds. Coronaviruses were named because the spike proteins known to facilitate viral attachment and cell entry appear like a halo on the virus surface when viewed under an electron microscope. Coronaviruses are roughly spherical with a diameter ranging from 118 nm to 136 nm. The coronavirus genome, which ranges from 26 kb to 32 kb, is the largest among all RNA viruses, including RNA viruses that have segmented genomes. Until 2019, six coronaviruses have been associated with human diseases:

- severe acute respiratory syndrome-related coronavirus (SARS-CoV),
- Middle East respiratory syndrome coronavirus (MERS-CoV),
- human coronavirus 229E (HCoV-229E),
- human coronavirus OC43 (HCoV-OC43),
- human coronavirus NL63 (HCoV-NL63), and
- human coronavirus HKU1 (HCoV-HKU1)<sup>[1]</sup>.

In 2019, a cluster of patients presenting with a respiratory disease were shown, by sequencing, to be infected with a novel coronavirus<sup>[2]</sup>. The coronavirus associated with this cluster was subsequently named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses<sup>[3]</sup>. SARS-CoV-2 is the seventh coronavirus known to infect humans. The disease caused by SARS-CoV-2 was designated as coronavirus infectious disease 2019 (COVID-19) by the World Health Organization (WHO)<sup>[4]</sup>.

The host range for SARS-CoV-2 is not yet fully defined. SARS-CoV-2 is a beta-coronavirus. The receptor for SARS-CoV-2 is the angiotensin-converting enzyme 2 (ACE2). ACE2 is a cell-surface, zinc-binding carboxypeptidase involved in regulation of cardiac function and blood pressure. It is expressed in epithelial cells of the lung and the small intestine, which are the primary targets of SARS-CoV-2, as well as the heart, kidney, and other tissues.

SARS-CoV-2 replicates in the upper and lower respiratory tracts and is transmitted by droplets and aerosols and most likely other contact with asymptomatic and symptomatic infected persons. The basic reproduction number ( $R_0$ ) of the original variant is between 2 and 3, but significantly more contagious variants have developed. The median incubation period is 5,7 (range 2 to 14) days<sup>[5]</sup>. Similarly to SARS and MERS, superspreading events have been reported, with a dispersion parameter (kappa) estimated at 0,1. Most infections are uncomplicated, and 5 % to 10 % of patients are hospitalized mainly due to pneumonia with severe inflammation. However, complications include respiratory and multiorgan failures. Risk factors for the complicated disease increase with age and include hypertension, diabetes, chronic cardiovascular and chronic pulmonary diseases, and immunodeficiency.

Clinical management of COVID-19 and control of infections and spread of SARS-CoV-2 require effective and efficient in vitro diagnostics. There are a number of tests and kits in use for the detection of SARS-CoV-2 and the number of methods will continue to increase. Acceptable design, development and establishment of quality SARS-CoV-2 diagnostics based on nucleic acid detection methods is critical to ensure COVID-19 infection control. Establishing indices for conducting comprehensive quality evaluation of these methods and kits both during development and in routine application will ensure the accuracy of the test results and support epidemic prevention and control. This document provides requirements and recommendations to consider for the quality practice of SARS-CoV-2 nucleic acid amplification methods.

# **In vitro diagnostic test systems — Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods**

## **1 Scope**

This document provides requirements and recommendations for the design, development, verification, validation and implementation of analytical tests for detecting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using nucleic acid amplification. It addresses pre-examination, examination and post-examination process steps for human specimens.

This document is applicable to medical laboratories. It is also intended to be used by in vitro diagnostic developers and manufacturers, as well as by institutions and organizations supporting SARS-CoV-2 research and diagnostics.

This document does not apply to environmental samples.

## **2 Normative references**

There are no normative references in this document.

**koniec náhľadu – text ďalej pokračuje v platenej verzii STN**